[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Bick, 2019 - Google Patents

Hereditary plasma protein disorders

Bick, 2019

Document ID
11251203845257291435
Author
Bick R
Publication year
Publication venue
Basic Concepts Of Hemostasis

External Links

Snippet

The hemophilias are characterized as hereditary coagulation factor defects with a clinical bleeding tendency, a prolonged activated partial thromboplastin time and a normal prothrombin time. Hemophilia was first recognized in Talmud writings of the second century …
Continue reading at www.taylorfrancis.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen

Similar Documents

Publication Publication Date Title
Al-Mondhiry et al. Fibrinogen"" New York"--an abnormal fibrinogen associated with thromboembolism: functional evaluation
Girolami et al. A ‘new’congenital haemorrhagic condition due to the presence of an abnormal factor X (factor X Friuli): study of a large kindred
Gill et al. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects
Lee et al. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding
Weinstein et al. Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate
Girolami et al. Prothrombin Padua: A “new” congenital dysprothrombinemia
Biggs et al. Tissue extract and the contact reaction in blood coagulation
Massicotte et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults
Hughes et al. Diabetes, a hypercoagulable state? Haemostatic variables in newly diagnosed type 2 diabetic patients
Bandello et al. Hypercoagulability and high lipoprotein (a) levels in patients with central retinal vein occlusion
NO148142B (en) PROCEDURE FOR THE PREPARATION OF A BLOOD COAGULATING PROCEDURE FROM HUMAN BLOOD PLASMA
Soff et al. Familial multiple coagulation factor deficiencies
CONLON et al. Telangiectasia and von Willebrand's disease in two families
Arnold et al. Coagulation factor activity during neonatal extra-corporeal membrane oxygenation
Haverkate et al. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis
Perry et al. Clinical and laboratory evaluation of thrombophilia
Marchi et al. Dysregulated coagulation associated with hypofibrinogenaemia and plasma hypercoagulability: implications for identifying coagulopathic mechanisms in humans
Bick Hereditary plasma protein disorders
Girolami et al. Chromogenic Substrate (S-2238) Prothrombin Assay in Prothrombin Deficiencies and Abnormalities. Lack of Identity with Clotting Assays in Congenital Dysprothrombinemias.
Bowie et al. Disappearance rates of coagulation factors: transfusion studies in factor‐deficient patients
Soslau et al. Desmopressin-induced improvement in bleeding times in chronic renal failure patients correlates with platelet serotonin uptake and ATP release
Smith et al. The prolonged bleeding time in hemophilia A: comparison of two measuring technics and clinical associations
JOHNSON et al. Effect of oral anticoagulant (Marcumar) on prothrombin and related components in blood coagulation
Sniecinski et al. Reduced levels of fibrin (antithrombin I) and antithrombin III underlie coagulopathy following complex cardiac surgery
Angelos et al. Coagulation studies: prothrombin time, partial thromboplastin time, bleeding time